Plain-English translation of NCT03728673 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether escitalopram, an antidepressant medication, can help protect or improve thinking and memory in people with grade IV glioma (a serious brain cancer). Up to 85% of glioma patients experience problems with memory, attention, and planning—either from the tumor itself or from cancer treatments like radiation and chemotherapy. The study will see if taking this medication daily for three months alongside standard cancer treatment can help preserve brain function and quality of life.
Many brain cancer patients struggle with cognitive problems after treatment, which affects their independence and wellbeing. This medication may help protect brain health and support mental function during a vulnerable time, but it hasn't been formally tested for this purpose in glioma patients yet.
You likely qualify if…
You likely don't qualify if…
You would take a daily capsule of the medication for 90 days while receiving your standard cancer treatment (chemotherapy and/or radiation). During the study, you would complete thinking and memory tests, brain imaging scans, and questionnaires about your mood and quality of life to measure whether the medication helps protect your cognitive function. The study involves about 20 participants total and is currently recruiting.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States